Tickborne Disease

$500.00Price
  • Tickborne diseases have more than doubled in 13 years and are 77% of all vector-borne disease reports
  • The most common tickborne diseases (TBDs) in the United States are Anaplasmosis, Babesiosis, Bartonella infections, Ehrlichiosis, Rickettsiosis, Rocky Mountain spotted fever (RMSF), and Lyme disease
  • Lyme Disease accounts for the majority (82%) of all tickborne disease cases

 

Ticks usually need between 24 and 72 hours to effectively transmit any diseases they are carrying and, if found in time on the host, can be removed before they transmit infectious microorganisms to the host.

 

Because many symptoms of tickborne diseases are generic or mimic other conditions, these diseases often go undiagnosed for months, increasing the suffering and disease progression of the patient.

 

Not Available in New York state
Only healthcare providers licensed in their state may order laboratory testing.

  • Symptoms

    Tickborne diseases can be acquired throughout the United States from a variety of ticks, which carry and pass on different microorganisms to humans and animals. Symptoms may be generic and have overlap with other conditions, and therefore, be difficult to associate with a tickborne disease.

    Symptoms Associated with Tickborne Diseases Include:

    • Fever and/or chills
    • headache
    • Bell’s palsy
    • neck stiffness
    • fatigue
    • muscle or joint aches/pains
    • GI symptoms : nausea, vomiting, diarrhea
    • rash
    • loss of appetite
    • weight loss
    • change in cognitive or psychological status
    • anemia
    • enlarged, tender lymph nodes
    • painful abdomen
    • dizziness or shortness of breath
    • numbness or weakness in limbs

    Tickborne disease symptoms and disease progression can also often be more severe in the elderly and immunocompromised.

  • Markers Measured

    Vibrant’s Tickborne Diseases panel includes two tests:

    1) PCR detection of different bacterial species that cause tickborne diseases (Anaplasma, Babesia, Bartonella, Borrelia, Ehrlichia, Rickettsia species)

    2) Protein microarray detection of bacterial antigens that cause tickborne diseases (Anaplasma, Babesia, Borellia, Bartonella, Ehrlichia and Rickettsia species)

    Antigens we test for include:

    • Borrelia burgdorferi VlsE1 IgM
    • Borrelia burgdorferi C6 peptide IgM
    • Borrelia burgdorferi spp. 18 kDa IgM
    • Borrelia burgdorferi spp. 23-25 kDa IgM
    • Borrelia burgdorferi spp. 28 kDa IgM
    • Borrelia burgdorferi spp. 30 kDa IgM
    • Borrelia burgdorferi spp. 31 kDa IgM
    • Borrelia burgdorferi spp. 34 kDa IgM
    • Borrelia burgdorferi spp. 39 kDa IgM
    • Borrelia burgdorferi spp. 41 kDa IgM
    • Borrelia burgdorferi spp. 45 kDa IgM
    • Borrelia burgdorferi spp. 58 kDa IgM
    • Borrelia burgdorferi spp. 66 kDa IgM
    • Borrelia burgdorferi spp. 83-93 kDa IgM
    • Borrelia burgdorferi VlsE1 IgG
    • Borrelia burgdorferi C6 peptide IgG
    • Borrelia burgdorferi spp. 18 kDa IgG
    • Borrelia burgdorferi spp. 23-25 kDa IgG
    • Borrelia burgdorferi spp. 28 kDa IgG
    • Borrelia burgdorferi spp. 30 kDa IgG
    • Borrelia burgdorferi spp. 31 kDa IgG
    • Borrelia burgdorferi spp. 34 kDa IgG
    • Borrelia burgdorferi spp. 39 kDa IgG
    • Borrelia burgdorferi spp. 41 kDa IgG
    • Borrelia burgdorferi spp. 45 kDa IgG
    • Borrelia burgdorferi spp. 58 kDa IgG
    • Borrelia burgdorferi spp. 66 kDa IgG
    • Borrelia burgdorferi spp. 83-93 kDa IgG
    • Borrelia burgdorferi spp.
    • Borrelia afzelii
    • Borrelia garinii
    • Borrelia miyamotoi IgM
    • Borrelia hermsii IgM
    • Borrelia turicatae IgM
    • Borrelia miyamotoi IgG
    • Borrelia hermsii IgG
    • Borrelia turicatae IgG
    • Borrelia TBRF spp.
    • Borrelia lonestari
    • Borrelia miyamotoi

    Babesiosis (IgG, IgM, and PCR)

    • Babesia microti IRA IgM
    • Babesia microti p32 IgM
    • Babesia microti p41 IgM
    • Babesia microti IRA IgG
    • Babesia microti p32 IgG
    • Babesia microti p41 IgG
    • Babesia microti
    • Babesia duncani

    Bartonellosis (IgG, IgM, and PCR)

    • Bartonella henselae 17 kDa IgM
    • Bartonella henselae 26 kDa IgM
    • Bartonella henselaeSucB IgM
    • Bartonella henselae 17 kDa IgG
    • Bartonella henselae 26 kDa IgG
    • Bartonella henselaeSucB IgG
    • Bartonella spp.

    Human Monocytic Ehrlichiosis (HME) and Human Granulocytic Anaplasmosis (HGA) (IgG, IgM, and PCR)

    • Anaplasma phagocytophilum Msp5 IgM
    • Anaplasma phagocytophilum Msp5 IgM
    • Anaplasma phagocytophilum Msp5 IgG
    • Anaplasma phagocytophilum p44 IgG
    • Anaplasma phagocytophilum
    • Ehrlichia chaffeensis
    • Ehrlichia ewingii

    Chlamydophila pneumoniae (IgG, IgM, and PCR)

    • Chlamydophila pneumoniae IgM
    • Chlamydophila pneumoniae IgG
    • Chlamydophila pneumoniae

    Mycoplasma PCR

    • Mycoplasma spp.

    Rocky Mountain Spotted Fever PCR

    • Rocky Mountain Spotted PCR Fever

    Tularemia PCR

    • Francisella spp.
  • FAQs

    Do I need to be fasting for the Tickborne Diseases test?

    As with all antibody testing, fasting is not required.

  • About The Test

    The Vibrant Immunochip is made from recombinant proteins of several species of Borrelia burgdorferi, and not just from B31 used by other western blot tests. Vibrant criteria for detection has higher sensitivity and specificity than the two-tier testing by CDC criteria, as demonstrated by internal studies. This eliminates doubt for clinicians.

    The Vibrant Tickborne Diseases panel is the first of its kind to be run on a silicon micro-array platform, providing the highest level of specificity and sensitivity in the industry for detecting tickborne diseases.

    Patients often present with a range of non-specific symptoms that may be Lyme, or other conditions that have symptom overlap. Patients with diagnosed Lyme may also experience resurgence of symptoms, which might suggest co-infections. Co-infections are complex and should be included in an initial screen of Lyme and related illnesses.

    Vibrant has the most comprehensive antibody (indirect) and DNA (direct) test for detection of Lyme and co-infections that, in most cases, can assist the clinician in assessing these situations and lead to the correct diagnosis.

    Because standard treatment for tickborne diseases usually involves courses of antibiotics that are prolonged, this can also leave the patient at risk for multiple chronic inflammatory symptoms or conditions due to impact to the microbiome. It is recommended that patients being treated for tickborne diseases undergo regular microbiome screening during antibiotic therapy, such as the Vibrant Gut Zoomer or Vibrant Gut Pathogens tests.

  • Shipping & Handling

    Vibrant Wellness Lab Tests are Shipped for free within 3-5 business days and include free return shipping instructions.

  • HIPPA Compliance Agreement

    All of your personal information, including the results of your report are processed through Verified HIPPA complient software provided by Vibrant America. 

     

    As a service provider, IMBTherapies does not maintian owndership of any personal medical records provided to our clients on any company computers or devices.

     

    You will always have the ability to sign in to a client portal and view your reports, or request a copy of your report be sent to you by contacting IMBTherapies.com be sent to you in the case that you loose any of your documents.   

  • Regulatory Statement

    Vibrant testing does not demonstrate absolute positive and negative predictive values for any disease state or condition. Its clinical utility has not been fully established. Vibrant validates the accuracy and precision of the testing but not of its clinical or diagnostic value. So these tests are for wellness and informational purpose only. Vibrant is actively doing clinical research on these samples, de-identified from patients under an IRB and will make research publications towards the same as and when the clinical utility is well established. These tests have been laboratory developed and their performance characteristics determined by Vibrant America LLC, a CLIA-certified laboratory performing the test CLIA#:05D2078809. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. Content provided for informational purposes only and should not be construed as medical advice. Content provided to help you make a healthy lifestyle, dietary, and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. Please consult with your healthcare practitioner for diagnosis and treatment considerations. The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile.